Astrazeneca Plc (AZN) 33.05 $AZN Astrazeneca (A
Post# of 273246
Posted On: 09/07/2016 11:14:49 AM
Astrazeneca Plc (AZN) 33.05 $AZN
Astrazeneca (AZN) Presents Benralizumab Phase III Data
Zacks Equity Research - Zacks Investment Research - Tue Sep 06, 8:08AM CDT
AstraZeneca plc, (AZN) recently announced further results from two pivotal phase III trials on its respiratory disease candidate, benralizumab, for the treatment of severe asthma.
ANIP: 61.17 (-0.38), GERN: 3.03 (+0.01), AZN: 33.05 (-0.04), ANIK: 48.54 (+0.20)
Benralizumab Phase III Trials Show Positive Results in Severe Asthma
BusinessWire - Mon Sep 05, 7:00AM CDT
Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype, as indicated by the presence of eosinophils in their blood.
AZN: 33.05 (-0.04)
Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:33AM CDT
Biogen (BIIB) granted Fast Track designation in the U.S. for aducanumab for the treatment of early stage Alzheimer's disease.
BIIB: 311.92 (+1.25), AZN: 33.05 (-0.04), LLY: 78.65 (+0.14), ANIK: 48.54 (+0.20)
AstraZeneca Asthma Drug Symbicort Positive in Safety Trial
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:21AM CDT
AstraZeneca PLC (AZN) announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone.
BSTC: 36.43 (+0.33), AZN: 33.05 (-0.04), OHRP: 2.74 (+0.04)
AstraZeneca Announces SYMBICORT Demonstrated Comparable Risk of Serious Asthma-Related Events and Lower Risk of Asthma Exacerbations Compared to Budesonide Alone
BusinessWire - Wed Aug 31, 4:00PM CDT
AstraZeneca today announced results from the SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol LABA (long-acting beta2-adrenergic agonist) safety study showing patients with controlled and uncontrolled asthma had a comparable risk of serious asthma-related events and a lower risk of asthma exacerbations when formoterol was combined with budesonide versus budesonide alone.
AZN: 33.05 (-0.04)
SmarTrend Watching for Potential Rebound in Shares of AstraZeneca After 1.51% Loss
Comtex SmarTrend(R) - Wed Aug 31, 1:35PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $32.61 to a high of $32.84. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $32.78 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 33.05 (-0.04)
AstraZeneca Falls 1.51% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Aug 31, 1:33PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $32.61 to a high of $32.84. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $32.78 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 33.05 (-0.04)
Array (ARRY) Presents Positive Cardiovascular Trial Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 10:28AM CDT
Array BioPharma (ARRY) presented positive results from a phase II study on its pipeline candidate, ARRY-797, at the European Society of Cardiology Congress 2016 in Rome, Italy.
ANIP: 61.17 (-0.38), AZN: 33.05 (-0.04), ARRY: 3.60 (unch)
Upgrade Alert for AstraZeneca (AZN)
Comtex SmarTrend(R) - Tue Aug 30, 3:23AM CDT
AstraZeneca (NYSE:AZN) was upgraded from Hold to Buy at Argus Research today. The stock closed yesterday at $33.30 on volume of 2.5 million shares, below average daily volume of 3.7 million. AstraZeneca PLC is a holding company. Through its subsidiaries, the Group researches, manufactures and sells pharmaceutical and medical products. The Group focuses its operations on seven therapeutic areas: Gastrointestinal, Oncology, Cardiovascular, Respiratory, Central Nervous System, Pain Control, Anaesthesia and Infection.
AZN: 33.05 (-0.04)
Dow 30 Stock Roundup: Pfizer's Big Buy, Boeing's Big Win
Swarup Gupta - Zacks Investment Research - Fri Aug 26, 8:24AM CDT
The Dow suffered losses over the week, weighed down by a number of factors.
MDVN: 80.84 (unch), JNJ: 119.55 (-0.20), GE: 30.93 (-0.12), GS: 169.59 (+0.26), PFE: 34.83 (+0.06), AZN: 33.05 (-0.04), MYL: 40.48 (+0.08), BWXT: 39.29 (+0.07), BA: 132.99 (unch), VZ: 53.47 (-0.04), MS: 31.73 (-0.02)
Company News for August 25, 2016
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 8:53AM CDT
Companies In The News are: INTU,PFE,AZN,LZB,EXPR
LZB: 26.91 (-0.05), EXPR: 11.83 (+0.14), AZN: 33.05 (-0.04), PFE: 34.83 (+0.06), INTU: 111.30 (-0.07)
A Closer Look at AstraZeneca Following the Sale of its Molecule Antibiotics Business to Pfizer
ACCESSWIRE - Thu Aug 25, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / August 25, 2016 / AstraZeneca PLC is a biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. Register with us now for your free membership and gain access to our Healthcare reports at: www.rdinvesting.com/subscribe-today/.
AZN: 33.05 (-0.04)
Drug Makers Stocks under Review -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Thu Aug 25, 6:30AM CDT
Stock-Callers.com has initiated research reports on the following Major Drug Manufacturers in the Healthcare sector: Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). On Wednesday, August 17, 2016, Brean Capital downgraded the sector to "Underweight" on technical indicators such as deteriorating relative strength, price momentum, and momentum of breadth. Learn more about these stocks by downloading their free research reports in PDF format at: http://stock-callers.com/registration
AZN: 33.05 (-0.04), LLY: 78.65 (+0.14), GSK: 43.92 (-0.07), BMY: 57.18 (+0.22)
Business Highlights
By The Associated Press - AP - Wed Aug 24, 4:24PM CDT
___
AGN: 237.98 (-1.14), AZN: 33.05 (-0.04), PFE: 34.83 (+0.06)
Pfizer on buying spree with AstraZeneca antibiotics deal
By LINDA A. JOHNSON - AP - Wed Aug 24, 4:11PM CDT
TRENTON, N.J. (AP) — Drugmaker Pfizer Inc. is continuing its shopping spree with its fourth acquisition since the April collapse of its planned $160 billion megadeal to buy rival Allergan PLC and move its headquarters, on paper, to Allergan's base in lower-tax Ireland.
AGN: 237.98 (-1.14), AZN: 33.05 (-0.04), PFE: 34.83 (+0.06), ANAC: 99.06 (-0.14)
Market News Over Summer Vacation: PFE, AZN, TSLA, LZB
Mark Vickery - Zacks Investment Research - Wed Aug 24, 9:11AM CDT
You know you're in a slow news cycle when the market focus is on a Janet Yellen speech that doesn't happen until Friday, and no one expects any action to come of it anyway.
MDVN: 80.84 (unch), LZB: 26.91 (-0.05), TSLA: 201.55 (-1.28), PFE: 34.83 (+0.06), AZN: 33.05 (-0.04)
Pfizer to Acquire Rights to AstraZeneca's Antibiotics Business
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 6:14AM CDT
Pfizer (PFE) entered into an agreement to acquire the rights to AstraZeneca's (AZN) late-stage small-molecule anti-infectives business in the ex-U.S. markets.
ANIP: 61.17 (-0.38), PFE: 34.83 (+0.06), AZN: 33.05 (-0.04)
Eli Lilly, AstraZeneca Alzheimer's Drug Gets FDA Fast Track
Arpita Dutt - Zacks Investment Research - Tue Aug 23, 7:59AM CDT
Eli Lilly (LLY) and AstraZeneca's (AZN) Alzheimer's disease treatment is currently in phase III studies.
ZTS: 52.01 (+0.72), AZN: 33.05 (-0.04), LLY: 78.65 (+0.14)
SmarTrend Watching for Potential Pullback in Shares of AstraZeneca After 1.07% Gain
Comtex SmarTrend(R) - Mon Aug 22, 12:39PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $33.56 to a high of $33.99. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $33.70 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 33.05 (-0.04)
Astrazeneca (AZN) Presents Benralizumab Phase III Data
Zacks Equity Research - Zacks Investment Research - Tue Sep 06, 8:08AM CDT
AstraZeneca plc, (AZN) recently announced further results from two pivotal phase III trials on its respiratory disease candidate, benralizumab, for the treatment of severe asthma.
ANIP: 61.17 (-0.38), GERN: 3.03 (+0.01), AZN: 33.05 (-0.04), ANIK: 48.54 (+0.20)
Benralizumab Phase III Trials Show Positive Results in Severe Asthma
BusinessWire - Mon Sep 05, 7:00AM CDT
Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype, as indicated by the presence of eosinophils in their blood.
AZN: 33.05 (-0.04)
Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:33AM CDT
Biogen (BIIB) granted Fast Track designation in the U.S. for aducanumab for the treatment of early stage Alzheimer's disease.
BIIB: 311.92 (+1.25), AZN: 33.05 (-0.04), LLY: 78.65 (+0.14), ANIK: 48.54 (+0.20)
AstraZeneca Asthma Drug Symbicort Positive in Safety Trial
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:21AM CDT
AstraZeneca PLC (AZN) announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone.
BSTC: 36.43 (+0.33), AZN: 33.05 (-0.04), OHRP: 2.74 (+0.04)
AstraZeneca Announces SYMBICORT Demonstrated Comparable Risk of Serious Asthma-Related Events and Lower Risk of Asthma Exacerbations Compared to Budesonide Alone
BusinessWire - Wed Aug 31, 4:00PM CDT
AstraZeneca today announced results from the SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol LABA (long-acting beta2-adrenergic agonist) safety study showing patients with controlled and uncontrolled asthma had a comparable risk of serious asthma-related events and a lower risk of asthma exacerbations when formoterol was combined with budesonide versus budesonide alone.
AZN: 33.05 (-0.04)
SmarTrend Watching for Potential Rebound in Shares of AstraZeneca After 1.51% Loss
Comtex SmarTrend(R) - Wed Aug 31, 1:35PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $32.61 to a high of $32.84. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $32.78 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 33.05 (-0.04)
AstraZeneca Falls 1.51% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Aug 31, 1:33PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $32.61 to a high of $32.84. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $32.78 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 33.05 (-0.04)
Array (ARRY) Presents Positive Cardiovascular Trial Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 10:28AM CDT
Array BioPharma (ARRY) presented positive results from a phase II study on its pipeline candidate, ARRY-797, at the European Society of Cardiology Congress 2016 in Rome, Italy.
ANIP: 61.17 (-0.38), AZN: 33.05 (-0.04), ARRY: 3.60 (unch)
Upgrade Alert for AstraZeneca (AZN)
Comtex SmarTrend(R) - Tue Aug 30, 3:23AM CDT
AstraZeneca (NYSE:AZN) was upgraded from Hold to Buy at Argus Research today. The stock closed yesterday at $33.30 on volume of 2.5 million shares, below average daily volume of 3.7 million. AstraZeneca PLC is a holding company. Through its subsidiaries, the Group researches, manufactures and sells pharmaceutical and medical products. The Group focuses its operations on seven therapeutic areas: Gastrointestinal, Oncology, Cardiovascular, Respiratory, Central Nervous System, Pain Control, Anaesthesia and Infection.
AZN: 33.05 (-0.04)
Dow 30 Stock Roundup: Pfizer's Big Buy, Boeing's Big Win
Swarup Gupta - Zacks Investment Research - Fri Aug 26, 8:24AM CDT
The Dow suffered losses over the week, weighed down by a number of factors.
MDVN: 80.84 (unch), JNJ: 119.55 (-0.20), GE: 30.93 (-0.12), GS: 169.59 (+0.26), PFE: 34.83 (+0.06), AZN: 33.05 (-0.04), MYL: 40.48 (+0.08), BWXT: 39.29 (+0.07), BA: 132.99 (unch), VZ: 53.47 (-0.04), MS: 31.73 (-0.02)
Company News for August 25, 2016
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 8:53AM CDT
Companies In The News are: INTU,PFE,AZN,LZB,EXPR
LZB: 26.91 (-0.05), EXPR: 11.83 (+0.14), AZN: 33.05 (-0.04), PFE: 34.83 (+0.06), INTU: 111.30 (-0.07)
A Closer Look at AstraZeneca Following the Sale of its Molecule Antibiotics Business to Pfizer
ACCESSWIRE - Thu Aug 25, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / August 25, 2016 / AstraZeneca PLC is a biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. Register with us now for your free membership and gain access to our Healthcare reports at: www.rdinvesting.com/subscribe-today/.
AZN: 33.05 (-0.04)
Drug Makers Stocks under Review -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Thu Aug 25, 6:30AM CDT
Stock-Callers.com has initiated research reports on the following Major Drug Manufacturers in the Healthcare sector: Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). On Wednesday, August 17, 2016, Brean Capital downgraded the sector to "Underweight" on technical indicators such as deteriorating relative strength, price momentum, and momentum of breadth. Learn more about these stocks by downloading their free research reports in PDF format at: http://stock-callers.com/registration
AZN: 33.05 (-0.04), LLY: 78.65 (+0.14), GSK: 43.92 (-0.07), BMY: 57.18 (+0.22)
Business Highlights
By The Associated Press - AP - Wed Aug 24, 4:24PM CDT
___
AGN: 237.98 (-1.14), AZN: 33.05 (-0.04), PFE: 34.83 (+0.06)
Pfizer on buying spree with AstraZeneca antibiotics deal
By LINDA A. JOHNSON - AP - Wed Aug 24, 4:11PM CDT
TRENTON, N.J. (AP) — Drugmaker Pfizer Inc. is continuing its shopping spree with its fourth acquisition since the April collapse of its planned $160 billion megadeal to buy rival Allergan PLC and move its headquarters, on paper, to Allergan's base in lower-tax Ireland.
AGN: 237.98 (-1.14), AZN: 33.05 (-0.04), PFE: 34.83 (+0.06), ANAC: 99.06 (-0.14)
Market News Over Summer Vacation: PFE, AZN, TSLA, LZB
Mark Vickery - Zacks Investment Research - Wed Aug 24, 9:11AM CDT
You know you're in a slow news cycle when the market focus is on a Janet Yellen speech that doesn't happen until Friday, and no one expects any action to come of it anyway.
MDVN: 80.84 (unch), LZB: 26.91 (-0.05), TSLA: 201.55 (-1.28), PFE: 34.83 (+0.06), AZN: 33.05 (-0.04)
Pfizer to Acquire Rights to AstraZeneca's Antibiotics Business
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 6:14AM CDT
Pfizer (PFE) entered into an agreement to acquire the rights to AstraZeneca's (AZN) late-stage small-molecule anti-infectives business in the ex-U.S. markets.
ANIP: 61.17 (-0.38), PFE: 34.83 (+0.06), AZN: 33.05 (-0.04)
Eli Lilly, AstraZeneca Alzheimer's Drug Gets FDA Fast Track
Arpita Dutt - Zacks Investment Research - Tue Aug 23, 7:59AM CDT
Eli Lilly (LLY) and AstraZeneca's (AZN) Alzheimer's disease treatment is currently in phase III studies.
ZTS: 52.01 (+0.72), AZN: 33.05 (-0.04), LLY: 78.65 (+0.14)
SmarTrend Watching for Potential Pullback in Shares of AstraZeneca After 1.07% Gain
Comtex SmarTrend(R) - Mon Aug 22, 12:39PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $33.56 to a high of $33.99. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $33.70 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 33.05 (-0.04)
(0)
(0)Scroll down for more posts ▼